India’s Shasun Pharmaceuticals has entered into a collaboration with Nanoparticle Biochem, Inc. (NBI) to develop a nanoparticle radioactive medicine NBI-29 to treat prostate cancer.
NBI-29 is a gold-based, radioactive to be administered as a brachytherapeutic agent. This nanoparticle has been found having very good anti-tumour activities in prostate cancer.
Early studies using NBI-29 nanoparticle drug could also be useful in treating other forms of malignancies including breast cancer, lung cancer, oral cancer besides prostate cancer.
NBI-29 is developed by Nanoparticle Biochem, Inc, a pioneer in the exciting field of nanomedicine which has developing and out licensed cancer therapy agents.
The Chennai-based Shasun would enter into a 50:50 joint venture with NBI to be known as Shasun NBI LLC to develop the nano medicine, the company said in a press announcement.
`’NBI is excited by the opportunity to join efforts with Shasun Pharmaceuticals in the development of a new nanoparticle-based pharmaceutical drug for use as a prostate cancer therapy agent,” Henry White, CEO of NBI has stated commenting on the collaboration.
5 per cent of NBI stakes is owned by University of Missouri, Colombia. University of Missouri, Colombia is one of the six labs in the USA that are part of the NIH driven ‘Alliance for Nanotechnology in Cancer’, the Shasun release said.
`’The tie-up with NBI and thereby with the University of Missouri at Colombia puts us in a dominant position in the vast expanding and exciting area of nanomedicine. We would have the best minds in nanomedicine working for us and are confident of creating significant Intellectual Property with wide ranging applications in future,” according to Vimal Kumar Shankarlal, managing director of Shasun.
Prostate cancer is the malignancy affecting the prostate gland in men. It is the second leading cancer among men worldwide. Prostate cancer is the sixth leading cause of cancer death in men.
The US$5.2 billion (2008) market for prostate cancer therapies is estimated to grow to USD 7.7 billion by 2015, Shasun release said.
Shasun Chemicals and Drugs has its headquarters in Chennai, Tamilnadu, India. Shasun acquired UK-based Rhodia Pharma through its wholly owned subsidiary Shasun Pharma Solutions Ltd.
Shasun Chemicals & Drugs Ltd posted revenues of Rs. 127 crore, a growth of 5 per cent compared to Q2 FY08 for the quarter ended September 30, 2008. For Q2 FY09, the company suffered forex losses of Rs. 13.50 crore (against Rs. 10.25 crore gain for Q2 last year) resulting in Net Loss of Rs.10.71 crore as against Net Profit of Rs 6.89 crore for the corresponding quarter of last year.
In July, Shasun Chemicals & Drugs Ltd launched its generic version of the recombinant streptokinase in the Indian market.
Shasun developed the biotherapeutic recombinant streptokinase under public-private-partnership. The technology for streptokinase was developed by the Chandigarh-based Institute of Microbial Technology (IMTech), a constituent laboratory of the Council of Scientific and Industrial Research (CSIR).
Streptokinase is used to break up blood clots in the blood vessels of leg veins, lungs and around the heart.
Streptokinase injection can dissolve blood clots that form in the heart, blood vessels, or lungs after a heart attack, or some other disease process.
Shasun has biotech facility at Velacherry, Chennai, southern India The facility is involved in the creation of biotechnology capabilities & capacities especially in the area of protein processing solutions to provide services for the biotech & pharmaceutical companies.